DCM
ARRY

Driehaus Capital Management’s Array Biopharma Inc ARRY Stock Holding History

Driehaus Capital Management’s Portfolio ARRY Stock Details ARRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-432,003
Closed -$20M – 614
2019
Q2 		$20M Sell
432,003
-1,376,576
-76% -$38.7M 0.63% 42
2019
Q1 		$44.1M Sell
1,808,579
-394,843
-18% -$8.22M 1.66% 6
2018
Q4 		$31.4M Sell
2,203,422
-193,311
-8% -$2.93M 1.34% 9
2018
Q3 		$36.4M Sell
2,396,733
-221,921
-8% -$3.4M 1.12% 9
2018
Q2 		$43.9M Sell
2,618,654
-78,292
-3% -$1.25M 1.49% 8
2018
Q1 		$44M Buy
2,696,946
+183,264
+7% +$2.94M 1.55% 8
2017
Q4 		$32.2M Buy
2,513,682
+416,277
+20% +$4.73M 1.22% 10
2017
Q3 		$25.8M Buy
+2,097,405
New +$19.5M 1.01% 14
2017
Q1 		– Sell
-419,218
Closed -$3.69M – 679
2016
Q4 		$3.69M Sell
419,218
-364,526
-47% -$2.68M 0.13% 170
2016
Q3 		$5.29M Buy
+783,744
New +$3.03M 0.18% 119

Other funds holding ARRY

ASN
Advisory Services Network Atlanta, Georgia $8.83B AUM 38.5% 1-Year Est. Return

Driehaus Capital Management's ARRY Position: Q3 2019 in Review

Driehaus Capital Management sold out of Array Biopharma Inc (ARRY) in Q3 2019, closing a stake of 432,003 shares — an estimated $20M sold.

Driehaus Capital Management first reported a position in ARRY in Q3 2016 and held it in 10 quarters. The position peaked at $44.1M in Q1 2019. 1 fund tracked by Wall St. Rank holds ARRY as of Q3 2019.

  • Driehaus Capital Management reported no remaining Array Biopharma Inc position as of Q3 2019 after selling out during the quarter.
  • Driehaus Capital Management sold 432,003 Array Biopharma Inc shares in Q3 2019, an estimated $20M.
  • Driehaus Capital Management first reported a position in Array Biopharma Inc in Q3 2016 and held it in 10 quarters.
  • Driehaus Capital Management's Array Biopharma Inc position peaked at $44.1M in Q1 2019.
  • 1 fund tracked by Wall St. Rank held Array Biopharma Inc as of Q3 2019.

Based on Driehaus Capital Management's 13F filing for Q3 2019, filed 14 Nov 2019.